Monoclonal antibody (hybrid tumor) for neutralizing CYR61 and applications thereof

Abstract

The invention relates to a monoclonal antibody capable of neutralizing CYR61 and applications thereof and a hybrid tumor capable of generating the monoclonal antibody. The technical scheme adopted by the invention relates to the monoclonal antibody secreted by the mouse anti-human CYR61 monoclonal antibody hybrid tumor CGMCC No.2766 or CGMCC No.2767, and the applications of the monoclonal antibody to preparation of a medicament for treating rheumatic disease, wherein the rheumatic disease is the chronic infectious arthritis. The invention has the advantages that: (1) the self-prepared monoclonal antibody can research pathogenesis of CYR61 in rheumatoid arthritis and can accurately position the expression of CYR61 and detect the CYR61 level of the blood serum and the lesion sites (such as joints); (2) the monoclonal antibody can be used for preparing a detection kit so as to distinguish clinical diagnostics of osteoarthritis and rheumatoid arthritis; and (3) the monoclonal antibody also can search the combination epitope where the CYR61 on the surface of the synovium and in the synovial of the rheumatoid arthritis patient can be neutralized, and provides the screening basis for preparing a humanized antibody which can neutralize the CYR61 in the next step.

Description

【Technical field】

[0001] The invention relates to a monoclonal antibody, in particular to a monoclonal antibody capable of neutralizing CYR61, its application and a hybridoma capable of producing the monoclonal antibody. 【Background technique】

[0002] Rheumatoid arthritis (RA) is one of the most common rheumatic diseases. RA is one of the most common autoimmune diseases. The global prevalence of RA averages 0.5-1%. In my country, the prevalence rate of RA is 0.45%, and the total number of new patients is about 4 million each year. The onset of RA is mostly young adults. Since there is no specific treatment drug to control the development of the disease, most patients lose their ability to work due to disability around 6-10 years after the onset of the disease. The disability rate can reach 50% and 70%. Therefore, RA seriously affects people's life and health, and at the same time, it also brings a heavy burden to my country's developing and sound medical insurance, and ...

Images